给药方案-话题@MedSci

#给药方案#

13篇内容 | 292人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1805815, encodeId=6e83180581524, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=两项阿柏西普8 mg关键性研究表明：89%的患者能够维持16周间隔给药方案, objectType=article, longId=739187, objectId=9974e3918754, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9974e3918754, replyNumber=0, likeNumber=40, createdTime=2023-05-22, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9974e3918754, moduleTitle=两项阿柏西普8 mg关键性研究表明：89%的患者能够维持16周间隔给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9974e3918754)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805814, encodeId=6e901805814bc, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Lancet：疫苗的疗效，给药方案，价格，存储，以及分配，影响全球疫情走向，富国已抢购全球约七成新冠疫苗，分配不公或延长疫情, objectType=article, longId=207115, objectId=7e1c20e1152c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e1c20e1152c, replyNumber=0, likeNumber=34, createdTime=2021-03-07, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e1c20e1152c, moduleTitle=Lancet：疫苗的疗效，给药方案，价格，存储，以及分配，影响全球疫情走向，富国已抢购全球约七成新冠疫苗，分配不公或延长疫情, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e1c20e1152c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805810, encodeId=da9818058109e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, objectType=article, longId=193319, objectId=6adc193319bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6adc193319bd, replyNumber=0, likeNumber=34, createdTime=2021-02-06, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6adc193319bd, moduleTitle=FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6adc193319bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805812, encodeId=2fea1805812e7, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, objectType=article, longId=195607, objectId=c7a119560ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7a119560ea0, replyNumber=0, likeNumber=37, createdTime=2020-08-10, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7a119560ea0, moduleTitle=2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7a119560ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805813, encodeId=7e2d180581370, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=JNNP:意大利多发性硬化患者中不同剂量那他珠单抗间隔给药方案的临床疗效, objectType=article, longId=202250, objectId=cdec202250b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdec202250b9, replyNumber=0, likeNumber=37, createdTime=2021-08-02, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdec202250b9, moduleTitle=JNNP:意大利多发性硬化患者中不同剂量那他珠单抗间隔给药方案的临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdec202250b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805811, encodeId=b73718058111e, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致, objectType=article, longId=195606, objectId=b86a1956069e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86a1956069e, replyNumber=0, likeNumber=33, createdTime=2020-10-24, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86a1956069e, moduleTitle=2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b86a1956069e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805809, encodeId=d1a71805809f5, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=剂型创新：来那度胺透皮给药方案的可行性, objectType=article, longId=185380, objectId=bab7185380eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bab7185380eb, replyNumber=0, likeNumber=41, createdTime=2020-12-07, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bab7185380eb, moduleTitle=剂型创新：来那度胺透皮给药方案的可行性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bab7185380eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805808, encodeId=a8e0180580838, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Ann Oncol：癌症患者，纳武单抗每4周480 mg给药方案靠谱吗？, objectType=article, longId=157761, objectId=9e4615e76119, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e4615e76119, replyNumber=0, likeNumber=38, createdTime=2019-05-02, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e4615e76119, moduleTitle=Ann Oncol：癌症患者，纳武单抗每4周480 mg给药方案靠谱吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e4615e76119)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805806, encodeId=377818058064a, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Lancet Haematology:缺铁女性如何补铁效果佳？不妨试试这些给药方案, objectType=article, longId=124771, objectId=d7fc124e716d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7fc124e716d, replyNumber=0, likeNumber=31, createdTime=2018-01-21, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7fc124e716d, moduleTitle=Lancet Haematology:缺铁女性如何补铁效果佳？不妨试试这些给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7fc124e716d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805807, encodeId=e11f180580e58, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Chest：四种静脉维生素C给药方案在危重症患者的药代动力学分析, objectType=article, longId=131724, objectId=e2dc131e24ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2dc131e24ed, replyNumber=0, likeNumber=33, createdTime=2018-12-08, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2dc131e24ed, moduleTitle=Chest：四种静脉维生素C给药方案在危重症患者的药代动力学分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2dc131e24ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805805, encodeId=c70f180580523, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！, objectType=article, longId=112635, objectId=d3d811263516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3d811263516, replyNumber=0, likeNumber=36, createdTime=2018-04-17, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3d811263516, moduleTitle=Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3d811263516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805803, encodeId=f2f51805803da, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案, objectType=article, longId=85088, objectId=aef18508830, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aef18508830, replyNumber=0, likeNumber=37, createdTime=2017-02-08, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aef18508830, moduleTitle=Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aef18508830)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1805804, encodeId=159c1805804bb, content=<a href='/topic/show?id=e976e885830' target=_blank style='color:#2F92EE;'>#给药方案#</a>, objectTitle=Crit Care：各种糖皮质激素以及给药方案用于感染性休克的疗效有差别吗？, objectType=article, longId=97241, objectId=faa29e2419f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faa29e2419f, replyNumber=0, likeNumber=29, createdTime=2017-09-18, rootId=0, userName=h.y200607_23674418, userId=4b632500090, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faa29e2419f, moduleTitle=Crit Care：各种糖皮质激素以及给药方案用于感染性休克的疗效有差别吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=faa29e2419f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

给药方案

2020-05-29

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

两项阿柏西普8 mg关键性研究表明：89%的患者能够维持16周间隔给药方案

2023-05-22

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Lancet：疫苗的疗效，给药方案，价格，存储，以及分配，影响全球疫情走向，富国已抢购全球约七成新冠疫苗，分配不公或延长疫情

2021-03-07

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

FDA批准默克PD-1单抗Keytruda的六周给药方案--减少了疫情期间患者的看病频率

2021-02-06

仁心济世 (审核中...)

前往app查看评论内容

#给药方案#

2020EAN大会速递丨Satralizumab在NMOSD患者中的PK/PD特征支持其给药方案

2020-08-10

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

JNNP:意大利多发性硬化患者中不同剂量那他珠单抗间隔给药方案的临床疗效

2021-08-02

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

2020EAN大会速递丨青少年NMOSD患者Satralizumab给药方案：与成年患者一致

2020-10-24

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

剂型创新：来那度胺透皮给药方案的可行性

2020-12-07

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Ann Oncol：癌症患者，纳武单抗每4周480 mg给药方案靠谱吗？

2019-05-02

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Lancet Haematology:缺铁女性如何补铁效果佳？不妨试试这些给药方案

2018-01-21

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Chest：四种静脉维生素C给药方案在危重症患者的药代动力学分析

2018-12-08

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！

2018-04-17

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Lancet：皮下注射甲氨蝶呤治疗中重度斑块型银屑病的强化给药方案

2017-02-08

h.y200607_23674418 (审核中...)

前往app查看评论内容

#给药方案#

Crit Care：各种糖皮质激素以及给药方案用于感染性休克的疗效有差别吗？

2017-09-18

科室
- - 订阅+
  - 更多科室
工具
服务